Corrigendum to “Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients” [Thromb. Res. 186 2020. 80–85]

The authors regret that data regarding thrombin generation, thrombin-antithrombin III, and prothrombin fragment F1 + 2 levels in males and females were exchanged by mistake, and thereby presented incorrectly in Tables 1, 2, and 3. Corrections for Table 1: Exchanges between sex were made in these parameters:-Mean lagtime with [95 Confidence intervals]-Mean peak thrombin with (standard deviation)-Mean time-to-peak thrombin with (standard deviation)-Mean endogenous thrombin potential with (standard deviation) Corrections for Table 2: Exchange between sex was made in these parameters: The 97.5 percentiles in “Subgroup intervals”. Corrections for Table 3: Exchange between sex was made in this parameter: Mean prothrombin fragment 1 + 2 with (standard deviation). Revision Corrected Table 1.Tabled 1Reference interval (mean Table ±1.96 x standard deviation) for thrombin generation in 124 healthy individuals. Data written in red indicate the corrected numbers. Corrected Table 2.Tabled 1Reference interval and subgroup intervals for thrombin-antithrombin complex levels (97.5th percentile) in healthy individuals.1Two missing values. 1Two missing values. Corrected Table 3.Tabled 1Reference interval for prothrombin fragment 1 + 2, (mean ± 1.96 x standard deviation) in healthy individuals. Subgroup intervals are presented as 95% confidence intervals. The authors would like to apologise for any inconvenience caused. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patientsThrombosis ResearchVol. 186PreviewThrombin generation, thrombin-antithrombin complex (TAT) levels, and prothrombin fragment 1+2 (F1+2) have shown potential as biomarkers of thromboembolic risk. The aims were to establish reference intervals for these three biomarkers and to assess the levels in patients with localized cancer compared with healthy individuals. Full-Text PDF